|
||
| Rebif News Channel: 52 articles |  |
|
|
|||||
|
|||||
|
|||||
| MS NEWS ARCHIVES: by week | |||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | |||||
 |
|||||
| |||||
| |||||
 Click to view 1280 MS Walk photos! | |||||
|
|||||
|
|||||
|
|||||
Monday
New Formulation Rebif for Relapsing Multiple Sclerosis Lowers Immunogenicity and Improves Tolerability
MADRID, SPAIN -- September 30, 2006 -- At 48 weeks into a 96 week phase 3b trial, a new formulation of Rebif (interferon beta-1a), researchers report that 44 mcg given subcutaneously 3 time a weeks significantly improves tolerability and reduces antibody formation compared with historical 48-week data on the currently available formulation of the drug in patients with relapsing multiple sclerosis (MS).
The data were presented here on September 28th at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
........."Rebif is already effective," said lead investigator Gavin Giovannoni, MD, consulting neurologist at the Institute of Neurology, University College in London, UK. "But here, with this new formulation, we see lower immunogenicity emerging, which is very important for relapse reduction. Notably, we also see a 3-fold lower rate of injection site reactions, and they were all mild to moderate," he added....
The new formulation has no animal or human-derived components. It is also delivered with a new auto-injector, which uses the thinnest needle in a ready-to-use syringe for use in MS treatment....
[PRESENTATION STUDY NAME: Reduced Immunogenicity With a New Formulation of Interferon-Beta-1a (Rebif): 24-Week Results of a Phase IIIb Study. Abstract P675]
MADRID, SPAIN -- September 30, 2006 -- At 48 weeks into a 96 week phase 3b trial, a new formulation of Rebif (interferon beta-1a), researchers report that 44 mcg given subcutaneously 3 time a weeks significantly improves tolerability and reduces antibody formation compared with historical 48-week data on the currently available formulation of the drug in patients with relapsing multiple sclerosis (MS).
The data were presented here on September 28th at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
........."Rebif is already effective," said lead investigator Gavin Giovannoni, MD, consulting neurologist at the Institute of Neurology, University College in London, UK. "But here, with this new formulation, we see lower immunogenicity emerging, which is very important for relapse reduction. Notably, we also see a 3-fold lower rate of injection site reactions, and they were all mild to moderate," he added....
The new formulation has no animal or human-derived components. It is also delivered with a new auto-injector, which uses the thinnest needle in a ready-to-use syringe for use in MS treatment....
[PRESENTATION STUDY NAME: Reduced Immunogenicity With a New Formulation of Interferon-Beta-1a (Rebif): 24-Week Results of a Phase IIIb Study. Abstract P675]